患者来源离体组织切片培养显示HPV阳性口咽头颈癌存在显著DNA双链断裂修复缺陷
该研究将新鲜患者来源的口咽鳞状细胞癌(OPSCC)样本制成400微米切片培养,经照射后定量53BP1焦点分析DNA双链断裂。HPV阳性OPSCC(n=14)残留断裂显著高于HPV阴性(n=12)(3 Gy:平均4.9 vs 1.2焦点/核,p<0.0001),ATM抑制在4例HPV阴性样本均有效但11例HPV阳性中仅2例有效,提示HPV阳性OPSCC存在内在DSB修复缺陷。
要点
- HPV阳性OPSCC组织切片照射后残留53BP1焦点显著多于HPV阴性(3 Gy:平均4.9 vs 1.2焦点/核,p<0.0001)。
- HPV阳性亚组中吸烟史<10包年者残留DSB高于≥10包年者(3 Gy:平均6.5 vs 3.2焦点/核,p=0.0105)。
- ATM抑制在4例HPV阴性样本均显著增加残留焦点,11例HPV阳性中仅2例有效。
核心结论
- 数据提供不依赖细胞系的证据,表明HPV阳性OPSCC存在内在DSB修复缺陷,强烈提示其对临床放射敏感性增强有实质性贡献。
- ATM抑制效果降低提示ATM编排的DNA损伤应答存在缺陷。
- 离体实验中残留53BP1核焦点较低可能识别DSB修复有效的HPV阳性患者,作者认为这些患者应潜在排除在减量治疗之外。
研究设计与样本
- 新鲜患者来源OPSCC样本切成400微米切片,在细胞培养插入物上培养。
- 切片照射,部分联合ATM抑制,2和24小时后固定冷冻。
- 通过免疫荧光显微镜定量与SCC标志物p63共染的核内53BP1焦点分析DSB。
- HPV阳性OPSCC组织n=14,HPV阴性OPSCC n=12。
主要发现
- 离体OPSCC肿瘤切片培养至少3天维持稳定氧合和增殖特征。
- 免疫荧光显微镜p63阳性区域与连续切片组织学确认的肿瘤细胞区域匹配,表明p63适合作为肿瘤细胞标志物。
- HPV阳性OPSCC组织(n=14)p63阳性核残留辐射诱导DSB显著高于HPV阴性OPSCC(n=12)(3 Gy:平均4.9 vs 1.2焦点/核;p<0.0001)。
- HPV阳性亚组中吸烟史<10包年患者残留DSB高于≥10包年者(3 Gy:平均6.5 vs 3.2焦点/核;p=0.0105)。
- 额外ATM抑制在全部4例HPV阴性样本中残留焦点大幅增加,但11例HPV阳性样本中仅2例显著增加。
关键数值与推荐
- HPV阳性OPSCC(n=14)vs HPV阴性OPSCC(n=12)3 Gy时残留53BP1焦点:平均4.9 vs 1.2焦点/核,p<0.0001。
- HPV阳性亚组吸烟史<10包年 vs ≥10包年3 Gy时残留焦点:平均6.5 vs 3.2焦点/核,p=0.0105。
- ATM抑制后残留焦点增加:4例HPV阴性样本全部有效,11例HPV阳性样本中仅2例有效。
临床怎么用
- 离体实验中残留53BP1核焦点较低可能识别DSB修复有效的HPV阳性患者,作者认为这些患者应潜在排除在减量治疗之外。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HPV-positive head and neck squamous cell carcinoma of the oropharynx (OPSCC) are more sensitive towards radiation than HPV-negative OPSCC. Two main theories exist regarding the underlying mechanism. Stronger lymphocyte infiltration points to an enhanced immunogenicity, whereas data from HPV-positive HNSCC cell lines suggest an enhanced cellular radiosensitivity based on a defect in DNA double-strand break (DSB) repair. The critical limitation of the latter theory is that the evidence was largely derived from a small number of established HPV-positive HNSCC cell lines. METHODS AND MATERIALS: Fresh patient-derived OPSCC samples were cut in 400 µm sections and cultured on cell culture inserts. Slice cultures were irradiated, in part combined with ATM inhibition, and fixed and frozen after 2 and 24 h. DSBs were analyzed by quantification of 53BP1 foci in nuclei co-stained with the SCC marker p63 via immunofluorescence microscopy. RESULTS: Ex vivo OPSCC tumor slice cultures maintained stable oxygenation and proliferation characteristics for at least 3 days. Areas of p63-positivity in immunofluorescence microscopy matched histologically confirmed tumor cell areas in serial sections, indicating the suitability of p63 as a tumor cell marker. p63-positive nuclei in HPV-positive OPSCC tissues (n = 14) showed profoundly elevated numbers of residual radiation-induced DSBs as compared to those from HPV-negative OPSCC (n = 12) (3 Gy: on average 4.9 vs. 1.2 foci per nucleus; p < 0.0001). Within the HPV-positive subgroup, samples derived from patients with a smoking history of less than 10 pack years demonstrated higher residual DSBs as compared to those derived from patients with 10 or more pack years (3 Gy: on average 6.5 vs. 3.2 foci per nucleus; p = 0.0105). Additional ATM inhibition resulted in a substantial increase in residual foci in all 4 HPV-negative samples tested but strikingly only in 2 out of 11 HPV-positive samples. CONCLUSIONS: In summary, our data provide robust, cell line-independent experimental evidence for an intrinsic DSB repair deficiency in HPV-positive OPSCC, strongly suggesting a meaningful contribution to the enhanced clinical radiosensitivity. The reduced effectiveness of ATM inhibition indicates a defect in the ATM-orchestrated DNA damage response. Lower numbers of residual 53BP1 nuclear foci in the ex vivo assay may identify HPV-positive patients with effective DSB repair who should potentially be excluded from de-intensification approaches.
引用
- Zech HB, Berger J, Mansour WY, et al. Patient derived ex vivo tissue slice cultures demonstrate a profound DNA double-strand break repair defect in HPV-positive oropharyngeal head and neck cancer. Radiother Oncol. 2022. PMID: 35093407. doi:10.1016/j.radonc.2022.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。